Market closed

Regulus Therapeutics Inc./$RGLS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Ticker

$RGLS
Trading on

Industry

Biotechnology

Employees

34

RGLS Metrics

BasicAdvanced
$119M
-
-$0.82
1.41
-
$119M
1.41
$2.05
$1.22
10.981
10.105
0.359
1.381
-316.71%
-54.42%
-95.00%
1.54
1.54
-2.414
-48.07%
-36.71%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGLS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Regulus Therapeutics Inc. stock?

Regulus Therapeutics Inc. (RGLS) has a market cap of $119M as of April 05, 2025.

What is the P/E ratio for Regulus Therapeutics Inc. stock?

The price to earnings (P/E) ratio for Regulus Therapeutics Inc. (RGLS) stock is 0 as of April 05, 2025.

Does Regulus Therapeutics Inc. stock pay dividends?

No, Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders as of April 05, 2025.

When is the next Regulus Therapeutics Inc. dividend payment date?

Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Regulus Therapeutics Inc.?

Regulus Therapeutics Inc. (RGLS) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.